The US Food and Drug Administration (USFDA) conducted audit at Indoco's
sterile manufacturing facility in Verna, Goa (Plant II) from 27th May'19 to 4th June'19, issuing 4 observations (483s). These observations are procedural in nature, not pertaining to data integrity. The Company will submit its responses shortly.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
